High-Dosage Fosfomycin Results in Adequate Plasma and Target-Site Exposure in Morbidly Obese and Nonobese Nonhyperfiltration Patients-Reference-Cited by-同舟云学术

High-Dosage Fosfomycin Results in Adequate Plasma and Target-Site Exposure in Morbidly Obese and Nonobese Nonhyperfiltration Patients

Published:2022-06-21 Issue:6 Volume:66 Page:
ISSN:0066-4804
Container-title:Antimicrobial Agents and Chemotherapy
language:en
Short-container-title:Antimicrob Agents Chemother

Author:

Busse D.¹²^ORCID,Simon P.³⁴⁵,Petroff D.⁴⁶,El-Najjar N.⁷,Schmitt L.¹²,Bindellini D.¹²,Dietrich A.³,Zeitlinger M.⁸^ORCID,Huisinga W.⁹,Michelet R.¹^ORCID,Wrigge H.⁴¹⁰¹¹,Kloft C.¹

Affiliation:

1. Freie Universitaet Berlin, Institute of Pharmacy, Department of Clinical Pharmacy and Biochemistry, Berlin, Germany

2. Graduate Research Training Program PharMetrX, Berlin/Potsdam, Germany

3. University of Leipzig Medical Centre, Department of Anesthesiology and Intensive Care Medicine, Leipzig, Germany

4. University of Leipzig, Integrated Research and Treatment Center (IFB) Adiposity Diseases, Leipzig, Germany

5. University of Augsburg, Department of Anesthesiology and Intensive Care Medicine, Augsburg, Germany

6. University of Leipzig, Clinical Trial Centre Leipzig, Leipzig, Germany

7. University Hospital Regensburg, Institute of Clinical Microbiology and Hygiene, Faculty of Medicine, Regensburg, Germany

8. Medical University of Vienna, Department of Clinical Pharmacology, Vienna, Austria

9. University of Potsdam, Institute of Mathematics, Potsdam, Germany

10. Bergmannstrost Hospital Halle, Department of Anesthesiology, Intensive Care, Emergency Medicine, and Pain Therapy, Halle, Germany

11. Medical Faculty, Martin-Luther-University Halle/Wittenberg, Halle, Germany

Abstract

The objectives of this study were the identification in (morbidly) obese and nonobese patients of (i) the most appropriate body size descriptor for fosfomycin dose adjustments and (ii) adequacy of the currently employed dosing regimens. Plasma and target site (interstitial fluid of subcutaneous adipose tissue) concentrations after fosfomycin administration (8 g) to 30 surgery patients (15 obese/15 nonobese) were obtained from a prospective clinical trial.

Publisher

American Society for Microbiology

Subject

Infectious Diseases,Pharmacology (medical),Pharmacology

Link

https://journals.asm.org/doi/pdf/10.1128/aac.02302-21

Reference47 articles.

1. Intravenous fosfomycin—back to the future. Systematic review and meta-analysis of the clinical literature

2. Pharmacokinetic Profile of Fosfomycin Trometamol

3. Fosfomycin as Partner Drug for Systemic Infection Management. A Systematic Review of Its Synergistic Properties from In Vitro and In Vivo Studies

4. World Health Organization. 2021. Executive summary: the selection and use of essential medicines 2021: report of the 23rd WHO Expert Committee on the selection and use of essential medicines. https://www.who.int/publications/i/item/WHO-MHP-HPS-EML-2021.01. Accessed 15 December 2021.

5. Prevalence of obesity and severe obesity among adults: United States, 2017-2018;Hales CM;NCHS Data Brief,2020

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Updated antimicrobial dosing recommendations for obese patients;Antimicrobial Agents and Chemotherapy;2024-05-02

2. Parenteral Fosfomycin in Gastrointestinal Surgery: A Systematic Review;Drug Research;2023-11-28

3. Population pharmacokinetics and pharmacodynamics of cefazolin using total and unbound serum concentrations in patients with high body weight;International Journal of Antimicrobial Agents;2023-04

4. Comprehensive guidance for antibiotic dosing in obese adults: 2022 update;Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy;2023-02-18